ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on February 15, 2018, covering events occurring on February 9, 2018. The filing details the Board of Directors' approval of 2017 performance-based compensation and specific expense reimbursements for named executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and expense arrangements.
Material Changes and Compensation Details
On February 9, 2018, the Board approved the following awards for 2017 performance:
- Adam S. Grossman (CEO): $136,000 cash bonus and 350,000 stock options.
- Dr. James Mond (CSO/CMO): $72,100 cash bonus and 150,000 stock options.
- Brian Lenz (CFO): $72,100 cash bonus and 150,000 stock options.
Stock Option Terms: The exercise price is $3.71 per share, based on the closing price on the grant date. Options vest over four years: 25% on the one-year anniversary and the remaining 75% monthly thereafter, fully vesting on February 9, 2022.
Relocation and Living Expenses: The Board approved the following payments in 2018:
- Mr. Grossman: One-time reimbursement of $212,000 for real estate relocation fees plus tax gross-up.
- Mr. Lenz: $5,000 per month for temporary housing through December 2018 plus tax gross-up.
- Dr. Mond: $8,000 per month for temporary living expenses through December 2018 plus tax gross-up.
Additionally, the Board noted that annual salaries for these officers will be revisited following the 2018 Annual Meeting of Stockholders.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. It is a disclosure of specific compensatory arrangements.
Key Facts for Investor Verification
- Verify the total cash outflow for executive bonuses ($280,200) and the impact of the $212,000 relocation reimbursement on the company's cash position.
- Confirm the dilution impact of the 650,000 newly granted stock options.
- Monitor the upcoming 2018 Annual Meeting for potential changes to executive base salaries.
- Note that 50% of the 2017 cash bonuses were prepaid in June 2017; this filing covers the remaining 50%.